Performance Marketing Agency Converge Appoints dentsu’s Shoshana Winter as CEO and MRY/AKQA/Media Monk’s Jason Whiting as CGO
October 07, 2024 09:30 ET
|
Converge Marketing
Performance marketing agency, Converge appoints Shoshana Winter as CEO and Jason Whiting as CGO to meet increasing client demand.
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
In Post-Theranos Era, Epi One's Transparent Approach to Cancer Detection Wins Investor Trust
October 04, 2024 15:00 ET
|
Epi One
New York, NY, Oct. 04, 2024 (GLOBE NEWSWIRE) -- In a world still reeling from the Theranos scandal, a new beacon of hope in cancer detection is rising – and this time, it's inviting the world to...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
October 01, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
September 30, 2024 08:00 ET
|
Ichnos Glenmark Innovation
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
September 27, 2024 08:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will...
Urteste Expands Development of Innovative Diagnostic Projects
September 26, 2024 10:29 ET
|
Urteste S.A.
Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET - Urteste S.A. (Warsaw Stock Exchange: URT), a biotechnology company...
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy
September 26, 2024 07:00 ET
|
EnnoDC
PRESS RELEASE EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy Versatile new technology featuring an...